Your browser doesn't support javascript.
loading
A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.
Welsh, Robert C; Roe, Matthew T; Steg, Philippe Gabriel; James, Stefan; Povsic, Thomas J; Bode, Christoph; Gibson, Charles Michael; Ohman, Erik Magnus.
Afiliação
  • Welsh RC; Mazankowski Alberta Heart Institute and University of Alberta, Edmonton, Alberta, Canada. Electronic address: Robert.Welsh@albertahealthservices.ca.
  • Roe MT; Division of Cardiology, Duke Clinical Research Institute, Duke Medicine, Durham, NC.
  • Steg PG; Université Paris-Diderot, Sorbonne Paris Cité, FACT, DHU-FIRE, AP-HP and INSERM U-1148, Paris, France; NHLI, Royal Brompton Hospital, Imperial College, London, United Kingdom.
  • James S; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
  • Povsic TJ; Division of Cardiology, Duke Clinical Research Institute, Duke Medicine, Durham, NC.
  • Bode C; University of Freiburg, Freiburg, Germany.
  • Gibson CM; Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
  • Ohman EM; Division of Cardiology, Duke Clinical Research Institute, Duke Medicine, Durham, NC.
Am Heart J ; 181: 92-100, 2016 Nov.
Article em En | MEDLINE | ID: mdl-27823698
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Agregação Plaquetária / Aspirina / Isquemia Miocárdica / Antagonistas do Receptor Purinérgico P2Y / Inibidores do Fator Xa Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Agregação Plaquetária / Aspirina / Isquemia Miocárdica / Antagonistas do Receptor Purinérgico P2Y / Inibidores do Fator Xa Idioma: En Ano de publicação: 2016 Tipo de documento: Article